logo1Vyvanse side effects are well known to Shire Pharmaceutical, the manufacturer. In fact, Shire was sent an official warning letter by the FDA for withholding important information on this drug’s dangers in 2011.

According to the FDA, a promotional magnet was used to entice doctors to prescribe this drug. By design, the drug representative’s business card covered the Vyvanse side effects risk information on the magnet.

This is a particularly damning paragraph from the warning letter to Shire:

“Vyvanse is associated with a number of serious risks, some of which are fatal, including a Boxed Warning concerning the potential for abuse. Vyvanse has numerous Contraindications, including use in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncratic reaction to sympathomimetic amines, glaucoma, agitated states, history of drug abuse; and use during or within 14 days following the administration of monoamine oxidase inhibitors. The PI includes Warnings related to serious cardiovascular events, psychiatric adverse events, long-term suppression of growth, seizures, and visual disturbances. The PI also contains a general Precaution regarding overdosage and use in patients who use other sympathomimetic drugs, as well as Precautions for patients with tics and Tourette’s syndrome. The most common adverse reactions associated with the use of Vyvanse include upper abdominal pain, decreased appetite, dizziness, dry mouth, irritability, insomnia, nausea, vomiting, and decreased weight.”

Shire, however, continues to manufacture this drug in spite of these serious and possibly fatal results. In the third quarter of 2012, Vyvanse sales were already $247 million and climbing.

Typical of pharmaceutical companies allied with psychiatry, their god is money. To understate the situation, the health and safety of our children is not foremost in the manufacturer’s minds.

And now Shire is campaigning to fill its coffers to overflowing by indoctrinating hesitant European parents and doctors with a bogus “White Paper.” This report is full of pseudo-scientific facts, and makes no bones about the importance Shire’s stakeholders have in the success of their latest money-making scheme.

Here is a quote from the White Paper report:

“The fact that this Expert White Paper was endorsed by a variety of stakeholders makes the messages it contains even stronger. It is my sincere hope that this document will help to ensure better recognition and better management of ADHD by all stakeholders in the wider healthcare arenas, in schools, in the criminal justice systems and in the workplace in each country across the EU.”

The consumer can educate himself and herself on the real facts of psychiatry and their financial connection to pharmaceutical companies. Facing up to the hazards of Vyvanse side effects is a good place to start. Following the money trail explains their actions.

Once the product’s customer disappears, so goes the product. One hopes the consumer will awaken before another generation of children is disabled for life by Vyvanse  side effects.

 

http://www.rxlist.com/vyvanse-side-effects-drug-center.htm

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm259167.htm

http://www.businessweek.com/ap/2013-02-01/shire-agrees-to-settle-adhd-drug-inquiry